drugset / Trial / NCT00280696

A Double-blind Confirmatory Trial of Levetiracetam in Epilepsy Patients With Partial Onset Seizures

NCT00280696

Phase 3 Completed 352 enrolled UCB Japan Co. Ltd.
RandomizedParallel-groupTriple-blindTreatment

Summary

A double-blind, randomized, multicenter, placebo controlled 5 parallel groups, confirmatory trial to evaluated the efficacy and safety of levetiracetam used as adjunctive treatment in patients from 16 to 65 years with epilepsy suffering from partial onset seizures.

Timeline

Start
2005-11
Primary completion
2007-11
Completion
2007-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Levetiracetam Other / unclassified 500 mg Oral
Subject Levetiracetam Other / unclassified 1000 mg Oral
Subject Levetiracetam Other / unclassified 2000 mg Oral
Subject Levetiracetam Other / unclassified 3000 mg Oral

Indications